GlassScriptPhysician profile
Jonathan Kahn Jones
NPI 1518385137
$11,979.63
in general payments reported to CMS, 2019-2025
22 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $503 · 2021: $8,785 · 2022: $1,139 · 2023: $578 · 2024: $518 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.14 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,818.22 | 2021-2025 | |
| Pfizer INC. | $712.82 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $502.75 | 2022 | |
| Allergan, INC. | $404.76 | 2020-2021 | |
| Ucb, INC. | $310.58 | 2020-2021 | |
| Amgen INC. | $295.64 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $191.90 | 2020-2021 | |
| Biogen, INC. | $191.32 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $98.50 | 2020-2021 | |
| Greenwich Biosciences, INC. | $86.08 | 2019 | |
| Lilly USA, LLC | $67.96 | 2020-2024 | Reyvow, Emgality |
| Lundbeck LLC | $63.80 | 2019-2021 | |
| Genzyme Corporation | $39.77 | 2021 | |
| Alexion Pharmaceuticals, INC. | $37.08 | 2019 | |
| Csl Behring | $34.26 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.17 | 2020-2021 | |
| Virtus Pharmaceuticals LLC | $19.99 | 2025 | Levorphanol Tartrate |
| Eisai INC. | $17.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.30 | 2021 | |
| Celgene Corporation | $15.29 | 2021 | |
| Alfasigma USA, INC. | $14.14 | 2022 | |
| Currax Pharmaceuticals LLC | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.